Oral FMT for Multiple Sclerosis

Recruiting in Palo Alto (17 mi)

Overseen byJoseph B Guarnaccia, MD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Griffin Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.

Eligibility Criteria

Adults aged 18-55 with a definite diagnosis of multiple sclerosis (MS) and an EDSS score between 1.0 and 6.5 can join this trial. They should not be on most MS drugs, but glatiramer acetate or interferon beta is okay. Participants must speak English, give consent, swallow capsules, and commit to several visits over five months.

Inclusion Criteria

You have been diagnosed with multiple sclerosis using specific medical guidelines from 2017.

You are between 18 and 55 years old.

Your Expanded Disability Status Score (EDSS) is between 1.0 and 6.5.

+2 more

Exclusion Criteria

You had a multiple sclerosis relapse within one month before the study starts.

You have previously used certain FDA-approved disease-modifying therapies.

You have taken antibiotics or corticosteroids within the last three months before the study starts.

+29 more

Participant Groups

This pilot study tests if fecal microbial transplant (FMT), given orally via capsules, could be a safe and effective treatment for MS in adults. The study will collect initial data from a small group of participants to assess the potential benefits.

1Treatment groups

Experimental Treatment

Group I: InterventionExperimental Treatment1 Intervention

Fecal microbial transplant capsules